Atherosclerotic Cardiovascular DiseasePhase 3VICTORION-2PNCT05030428
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
A Phase 3 study testing Inclisiran sodium 300 mg in people with Atherosclerotic Cardiovascular Disease, run by Novartis Pharmaceuticals at 983 sites in 50 countries.
Trial summary
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD). Read more about this study
- Who is it for?
- Ages 40 to 100 years
- Conditions the study is for
- Atherosclerotic Cardiovascular Disease
- What is being tested?
- Inclisiran sodium 300 mg
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 17,004 participants
- Where
- 983 sitesin 50 countries
- Study dates
- 23 Nov 2021to 10 May 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Fasting LDL-C ≥ 70 mg/dL at randomization visit
- Stable (greater than or equal to 4 weeks) and well-tolerated lipid-lowering regimen (including e.g. with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin greater than or equal to 40 mg QD or rosuvastatin greater than or equal to 20 mg QD
- Established CV disease defined as ANY of the following three conditions
- Spontaneous Myocardial infarction ≥ 4 weeks from screening visit
- History of ischemic stroke occurred ≥ 4 weeks prior to the Screening visit
- Symptomatic peripheral arterial disease (PAD) evidenced by either intermittent claudication with ankle brachial index (ABI) < 0.85, prior peripheral arterial revascularization procedure, or, amputation due to atherosclerotic disease.
Who cannot join
- Acute coronary syndrome, stroke, peripheral arterial revascularization procedure or amputation due to atherosclerotic disease < 4 weeks before screening visit
- Treatment with PCSK9 inhibitors (e.g. evolocumab, alirocumab) within 90 days or planned use post first study visit
- Planned or expected cardiac, cerebrovascular or peripheral artery surgery or re-vascularization within the 6 months after the first study visit
- Heart failure NYHA class III or IV
- Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver
- Previous exposure to inclisiran or any other non-mAb PCSK9-targeted therapy, either as an investigational or marketed drug within 2 years
Show all 10Show fewer
- Severe concomitant non-CV disease that is expected to reduce life expectancy to less than 5 years
- History of malignancy that required surgery radiation therapy and/or systemic therapy during the 3 years prior to the first study visit
- Pregnant or nursing (lactating) women
- Other protocol-defined inclusion/exclusion criteria may apply.
Trial locations and contacts
983 sites in 50 countries.
983 sites in 50 countries
United States271 sites
Abington Memorial Hospital
Abington, Pennsylvania, 19001
Biofortis Research
Addison, Illinois, 60101
Akron Hospital Summa Health System
Akron, Ohio, 44309
Albany Medical College
Albany, New York, 12206
New Mexico Heart Institute
Albuquerque, New Mexico, 87102
Christus Health Central Louisiana
Alexandria, Louisiana, 71301
PharmaTex Research LLC
Amarillo, Texas, 79106
Alaska Heart and Vascular
Anchorage, Alaska, 99508
Endeavor Health Clinical Op- NCH
Arlington Heights, Illinois, 60005
Aurora Denver Cardiology Associates
Aurora, Colorado, 80012
Rocky Mountain Regional VA Med Ctr
Aurora, Colorado, 80045
Central Cardiology Medical Center
Bakersfield, California, 93308
Sinai Ct for Throm Res and Drug Dev
Baltimore, Maryland, 21209
Louisiana Cardiology Associates
Baton Rouge, Louisiana, 70808
North Hills Medical Research Inc
Bedford, Texas, 76021
Metropolitan Cardiovascular Consultants Llc
Beltsville, Maryland, 20705
Belzoni Clinical Research
Belzoni, Mississippi, 39038
Bend Memorial Clinic
Bend, Oregon, 97701
Meridian Clinical Research
Binghamton, New York, 13901
UAB St Vincents
Birmingham, Alabama, 35211
Excel Medical Clinical Trials LLC
Boca Raton, Florida, 33434
Grace Research LLC
Bossier City, Louisiana, 71111
Tufts Medical Center
Boston, Massachusetts, 02111
Dana Farber Cancer Institute
Boston, Massachusetts, 02115
VA Boston Healthcare System
Boston, Massachusetts, 02132
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Progressive Clinical Research
Bountiful, Utah, 84010
Cardiovascular and Vein Center of Florida
Bradenton, Florida, 34209
Nova Clinical Research LLC
Bradenton, Florida, 34209
Bridgeport Hospital
Bridgeport, Connecticut, 06610
Burke Internal Medicine and Research
Burke, Virginia, 22015
Independence Health System Cardiovascular Consultants
Butler, Pennsylvania, 16001
Alliance Clinical
Canoga Park, California, 91303
Medical Univ Of South Carolina
Charleston, South Carolina, 29425
Novant Health Heart Vas Inst
Charlotte, North Carolina, 28204
Tryon Medical Partners PLLC
Charlotte, North Carolina, 28277
Cedar Crosse Research Ct
Chicago, Illinois, 60607
Chicago Clinical Research Inst
Chicago, Illinois, 60607
Inland Psychiatric Medical Group
Chino, California, 91710
Velocity Clin Research Springdale
Cincinnati, Ohio, 45246
University Of Cincinnati
Cincinnati, Ohio, 45267
Bay Care Medical Group
Clearwater, Florida, 33756
Univ Hosp Cleveland Medical Center
Cleveland, Ohio, 44106-5028
Johns Hopkins University
Columbia, Maryland, 21044
Columbia Heart Clinic
Columbia, South Carolina, 29203
Columbia VA Health Care System
Columbia, South Carolina, 29209
John Muir Physician Network Clinical Research Center
Concord, California, 94520
Javara Research
Conroe, Texas, 77384
Bassett Medical Center
Cooperstown, New York, 13326
Samaritan Cardiology
Corvallis, Oregon, 97330
Cardiovascular Associates Research
Covington, Louisiana, 70433
Louisiana Heart Center Research
Covington, Louisiana, 70433
Avant Research Associates LLC
Crowley, Louisiana, 70526
VA North Texas Health Care System
Dallas, Texas, 75216
Soltero Cardiovascular Research Center
Dallas, Texas, 75226
North Texas Endocrine Center
Dallas, Texas, 75231
Research Institute of Dallas PA
Dallas, Texas, 75231
Texas Health Physicians Group
Dallas, Texas, 75231
SW Family Medicine Associates
Dallas, Texas, 75235
Alina clinical trials
Dallas, Texas, 78503
Premier Cardiovascular Institute
Dayton, Ohio, 45414
Cardiology Research Associates
Daytona Beach, Florida, 32117
Hillcrest Medical Research
DeLand, Florida, 32720
Henry Ford Hospital
Detroit, Michigan, 48202
St Marys Medical Center
Duluth, Minnesota, 55805
David Turbay MD PLLC
El Paso, Texas, 79905
Elkhart Cardiology Group
Elkhart, Indiana, 46514
Meridian Clinical Research LLC
Endwell, New York, 13760
Horizon Research Group of Opelousas LLC
Eunice, Louisiana, 70535
Eastern Shore Research Institute
Fairhope, Alabama, 36532
Javara Research
Fayetteville, Georgia, 30214
AA Medical Research Center
Flint, Michigan, 48504
G and L Research LLC
Foley, Alabama, 36535
Javara Research
Forest, Virginia, 24551
Texas Health Physicians Group
Fort Worth, Texas, 76104
Texas Health Physicians Group
Fort Worth, Texas, 76107
Anderson Medical Research
Ft. Washington, Maryland, 20744
Triallogix
Fullerton, California, 92835
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Mercy Gilbert Medical Center
Gilbert, Arizona, 85297
Javara Inc
Glenn Dale, Maryland, 20769
Altru Health Research Dept.
Grand Forks, North Dakota, 58201
Healthy Heart Cardiology
Grand Rapids, Michigan, 49546
Cardiovascular Institute South ASC
Gray, Louisiana, 70359
Bon Secours Medical Group
Greenville, South Carolina, 29607
Prisma Health Upstate
Greenville, South Carolina, 29615
Wellmont CVA Heart Institute
Greenville, Tennessee, 37745
d-b-a Greenwich Cardio Assoc
Greenwich, Connecticut, 06830
Cooper University Health Care
Haddon Heights, New Jersey, 08035
Heart Clinic of Hammond
Hammond, Louisiana, 70403
Las Vegas Endocrinology
Henderson, Nevada, 89074
National Research Institute
Hialeah, Florida, 33013
Sister Life Research Inc
Hialeah, Florida, 33013
Zenith Clinical Research
Hollywood, Florida, 33021
Heart Care Associates P C
Hopewell, Virginia, 23860
Houston Methodist Hospital
Houston, Texas, 77030
UT Physicians Memorial Hermann
Houston, Texas, 77030
Orion Medical
Houston, Texas, 77034
Village Medical Village MD S Tx
Houston, Texas, 77084
Diabetes Lipid Management Center
Huntington Beach, California, 92648
Franciscan Health Services Research Center
Indianapolis, Indiana, 46237
University of Calif Irvine Med Cntr
Irvine, California, 92660
Jackson Heart Clinic
Jackson, Mississippi, 39216
VAMC Research-G V Sonny Montgomery Clinic
Jackson, Mississippi, 39216
Apex Cardiology Research Associates of Jackson
Jackson, Tennessee, 38301
The Jackson Clinic PA
Jackson, Tennessee, 38301
Westside Center for Clinical Research
Jacksonville, Florida, 32205
UF Health Science Center
Jacksonville, Florida, 32209
Baptist Heart Specialists
Jacksonville Beach, Florida, 32250
Gateway Cardiology PC
Jerseyville, Illinois, 62052
University of Kansas Hospital
Kansas City, Kansas, 66160
Kansas City VA Medical Center
Kansas City, Missouri, 64128
Kettering Medical Center
Kettering, Ohio, 45429
Turkey Creek Medical Center
Knoxville, Tennessee, 37934
Accellacare
Knoxville, Tennessee, 37938
UC San Diego Health
La Jolla, California, 92037
Trident Cardiology
Ladson, South Carolina, 29465
CV Ins of the South
Lafayette, Louisiana, 70503
United Vein and Vascular Centers
Lake Worth, Florida, 33461
FMC Science
Lampasas, Texas, 76550
Capitol Cardiology Associates
Lanham, Maryland, 20706
McLaren Greater Lansing
Lansing, Michigan, 48910
AB Clinical Trials
Las Vegas, Nevada, 89119
Clinical Research of South Nevada
Las Vegas, Nevada, 89121
Witham Heart Partners
Lebanon, Indiana, 46052
University of Kentucky College of Health Sciences
Lexington, Kentucky, 40536
Physician Research Collaboration
Lincoln, Nebraska, 68516
New Jersey Heart
Linden, New Jersey, 07036
ARcare Center for Clinical Research
Little Rock, Arkansas, 72205
Arkansas Clinical Research
Little Rock, Arkansas, 72205
East Texas Research Associates Inc.
Livingston, Texas, 77351
American Institute of Research
Los Angeles, California, 90017
Keck Medical Center USC
Los Angeles, California, 90033
University of California LA
Los Angeles, California, 90095
U of Louisville Rudd Heart and Lung
Louisville, Kentucky, 40202
Garden State Heart Care
Manalapan, New Jersey, 07726
Catholic Medical Center
Manchester, New Hampshire, 03062
North Shore Heart and Vascular
Mandeville, Louisiana, 70448
Clinical Trials Management LLC
Mandeville, Louisiana, 70471
Rama Research LLC
Marion, Ohio, 43302
CardioVoyage LLC
McKinney, Texas, 75071
Memphis Cardiology and Vein Ct
Memphis, Tennessee, 38119
Solaris Clinical Research
Meridian, Idaho, 83646
The Heart Center of Lake County
Merrillville, Indiana, 46410
Cardiovascular Associates of Mesa
Mesa, Arizona, 85206
Omega Clinical Research
Metairie, Louisiana, 70006
ActivMed Practices and Research
Methuen, Massachusetts, 01844
Infinite Clinical Research
Miami, Florida, 33133
A&A Research Group Inc
Miami, Florida, 33186
Inpatient Research Clinical LLC
Miami Lakes, Florida, 33014
RM Medical Research Inc
Miami Lakes, Florida, 33014
Indago Research and Health Ctr Inc
Miami Lakes, Florida, 33016
MyMichigan Medical Center Midland
Midland, Michigan, 48670
NYU Langone Hlth Card Assoc
Mineola, New York, 11501
University Of Minnesota
Minneapolis, Minnesota, 55455
FXM Clin Res Miramar LLC
Miramar, Florida, 33027
Clinical Trials of America LA LLC
Monroe, Louisiana, 71201
Lucas Research
Morehead City, North Carolina, 28557
Cardiovascular Research Of Northwest Indiana, Llc
Munster, Indiana, 46321
Family Medicine of Sayebrook
Myrtle Beach, South Carolina, 29588
Saltzer Health
Nampa, Idaho, 83686
Advanced Research for Health Improvement LLC
Naples, Florida, 34102
Barnum Medical Research Inc
Natchitoches, Louisiana, 71457
Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901
Crescent City Physicians Inc
New Orleans, Louisiana, 70115
Weill Cornell Medical Center
New York, New York, 10021
Icahn School of Med at Mt Sinai
New York, New York, 10029
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
York Clinical Research
Norfolk, Virginia, 23504
North Kansas City Hospital
North Kansas City, Missouri, 64116
Northport VA Medical Center
Northport, New York, 11768
Ocala Cardiovascular Research
Ocala, Florida, 34471
VA Med NWI Endocrine Studies R151
Omaha, Nebraska, 68105
CCT Research
Omaha, Nebraska, 68130
CV Ins of the South
Opelousas, Louisiana, 70570
Midwest Heart and Vascular Spec
Overland Park, Kansas, 66211
Oviedo Medical Research
Oviedo, Florida, 32765
MD Medical Research
Oxon Hill, Maryland, 20745
CTMD Research
Palm Springs, Florida, 33406
VA Palo Alto Health Care System
Palo Alto, California, 94304-1207
Alta Pharmaceutical Research Center
Peachtree Corners, Georgia, 30092
Broward Research Center
Pembroke Pines, Florida, 33024
SEC Clinical Research
Pensacola, Florida, 32503
Methodist Med Center Of Illinois
Peoria, Illinois, 61603
Discovery Clinical Trials
Pflugerville, Texas, 78660-3015
Elite Clinical Studies
Phoenix, Arizona, 85018
UPMC
Pittsburgh, Pennsylvania, 15213
Preferred Primary Care Physicians
Pittsburgh, Pennsylvania, 15236
Preferred Primary Care Physicians
Pittsburgh, Pennsylvania, 15243
Heartplace-Plano
Plano, Texas, 75075
Peace River Cardiovascular Center
Port Charlotte, Florida, 33952
Cardiovascular Res of Knoxville LLC
Powell, Tennessee, 37849
NC Heart and Vascular Research LLC
Raleigh, North Carolina, 27607
Dominion Medical Associates
Richmond, Virginia, 23219
The Valley Hospital
Ridgewood, New Jersey, 07450
Roanoke Heart Institute
Roanoke, Virginia, 24014
North Memorial Heart and Vascular Institute
Robbinsdale, Minnesota, 55422
Rochester Clinical Research
Rochester, New York, 14609
Adventist HealthCare Shady Grove Medical Center
Rockville, Maryland, 20850
Central Michigan University
Saginaw, Michigan, 48601
CentraCare Heart and Vascular Center
Saint Cloud, Minnesota, 56303
Regions Hospital
Saint Paul, Minnesota, 55101
Tidal Health Peninsula Regional Inc
Salisbury, Maryland, 21804
Accellacare of Salisbury
Salisbury, North Carolina, 28144
University of Texas Health Science Ctr
San Antonio, Texas, 78229-3900
South Texas Cardiovascular Consultants PLLC
San Antonio, Texas, 78229
Endeavor Clinical Trials
San Antonio, Texas, 78240
San Diego Veterans Medical Center
San Diego, California, 92161
West Coast Research LLC
San Ramon, California, 94582
Helping Hands Medical Associates INC
Santa Ana, California, 92704
Syrentis Clinical Research
Santa Ana, California, 92705
HonorHealth Heart Group Deer Valley
Scottsdale, Arizona, 85258
Virginia Mason Medical Centre
Seattle, Washington, 98101
Swedish Medical Center-Cardiovascular Research
Seattle, Washington, 98122
University of Washington
Seattle, Washington, 98195
Sherman Clinical Research
Sherman, Texas, 75090
Grace Research Llc
Shreveport, Louisiana, 71105
Sanford USD Medical Center
Sioux Falls, South Dakota, 57104
North Central Heart
Sioux Falls, South Dakota, 57105
Louisiana Heart Center Research
Slidell, Louisiana, 70458
Frontier Clinical Research LLC
Smithfield, Pennsylvania, 15478
Cardio Metabolic Institute
Somerset, New Jersey, 08873
Providence Hospital Patient Care Research
Southfield, Michigan, 48075
Encompass Clinical Research
Spring Valley, California, 91978
SIU School of Medicine
Springfield, Illinois, 62702
Prairie Heart Institute
Springfield, Illinois, 62769
Mercy Hospital
Springfield, Missouri, 65804
Heart House Research Foundation
Springfield, Ohio, 45504
St Louis V A Medical Center
St Louis, Missouri, 63125-4181
Gateway Cardiovascular Rsch Ctr Inc
St Louis, Missouri, 63128
Mercy South
St Louis, Missouri, 63128
St Louis Heart and Vascular
St Louis, Missouri, 63136
Advanced Medical Research Center
St. Petersburg, Florida, 33713
Stanford University Medical Center
Stanford, California, 94304
Javara Research
Stephenville, Texas, 76401
Manshadi Heart Institute
Stockton, California, 95204
State Uni of NY at Stony Brook
Stony Brook, New York, 11794-3362
Privia Medical Group Gulf Coast
Sugar Land, Texas, 77478
Clinical Research Inst of Arizona
Sun City West, Arizona, 85375
Universal Research Group LLC
Tacoma, Washington, 98405
New Tampa Health
Tampa, Florida, 33603
BayCare Medical Group Inc
Tampa, Florida, 33607
James A Haley Veterans Hospital
Tampa, Florida, 33612
Genesis Clinical Research
Tampa, Florida, 33614
BayCare Health System
Tampa, Florida, 33705
Ravessa Clinical Research
Tampa, Florida, 33880
Mercy Health St Vincent Med Ctr
Toledo, Ohio, 43608
Cotton O Neil Clinical Res Center
Topeka, Kansas, 66606
Harbor UCLA Medical Center
Torrance, California, 90502
Traverse Heart and Vascular
Traverse City, Michigan, 49684
Atlanta Heart Specialists LLC
Tucker, Georgia, 30084
Pima Heart And Vascular Clin Rch
Tucson, Arizona, 85741
Tennessee Center For Clinical Trials
Tullahoma, Tennessee, 37388
Oklahoma Heart Institute
Tulsa, Oklahoma, 74133
Cardiology Associates of North MS
Tupelo, Mississippi, 38801
Westchester Medical Center
Valhalla, New York, 10595
Blue Coast Research Center LLC
Vista, California, 92081
Kent County Memorial Hospital
Warwick, Rhode Island, 02886
Emerson Clinical Research Institute
Washington D.C., District of Columbia, 20020
Chase Medical Research LLC
Waterbury, Connecticut, 06708
Covenant Medical Center
Waterloo, Iowa, 50702
Cardiology Partners Clinical Research Institute
Wellington, Florida, 33449
Confluence Health Hospital
Wenatchee, Washington, 98801
Interv Cardiology Med Grp
West Hills, California, 91307
Ascension Via Christi Research
Wichita, Kansas, 67214
Winchester Medical Center
Winchester, Virginia, 22601
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, 27157
Yazoo Clinical Research .
Yazoo City, Mississippi, 39194
Yazoo Clinical Research
Yazoo City, Mississippi, 39194
Trinity Health Michigan Heart
Ypsilanti, Michigan, 48197
Southern Clinical Research
Zachary, Louisiana, 70791
China50 sites
Novartis Investigative Site
Beijing, Beijing Municipality, 100013
Novartis Investigative Site
Beijing, 100029
Novartis Investigative Site
Beijing, 100034
Novartis Investigative Site
Beijing, 100039
Novartis Investigative Site
Beijing, 100050
Novartis Investigative Site
Beijing, 100191
Novartis Investigative Site
Changchun, Jilin, 130000
Novartis Investigative Site
Changsha, Hunan, 410003
Novartis Investigative Site
Changsha, Hunan, 410011
Novartis Investigative Site
Changzhou, Jiangsu, 213004
Novartis Investigative Site
Chengdu, Sichuan, 610041
Novartis Investigative Site
Chongqing, 400016
Novartis Investigative Site
Dalian, Liaoning, 116011
Novartis Investigative Site
Foshan, Guangdong, 528000
Novartis Investigative Site
Guangzhou, Guangdong, 510080
Novartis Investigative Site
Guangzhou, Guangdong, 510515
Novartis Investigative Site
Guangzhou, 510000
Novartis Investigative Site
Guangzhou, 510280
Novartis Investigative Site
Hangzhou, Zhejiang, 310016
Novartis Investigative Site
Harbin, Heilongjiang, 150000
Novartis Investigative Site
Hohhot, Inner Mongolia, 010017
Novartis Investigative Site
Jiangyin, Jiangsu, 214499
Novartis Investigative Site
Jinan, Shandong, 250013
Novartis Investigative Site
Jinan, 250012
Novartis Investigative Site
Jingzhou, Hubei, 434020
Novartis Investigative Site
Lishui, Zhejiang, 323020
Novartis Investigative Site
Nanchang, Jiangxi, 330006
Novartis Investigative Site
Nanjing, Jiangsu, 210008
Novartis Investigative Site
Nanjing, Jiangsu, 210009
Novartis Investigative Site
Nanjing, Jiangsu, 211166
Novartis Investigative Site
Nanning, Guangxi, 530022
Novartis Investigative Site
Pingxiang, Jiangxi, 337000
Novartis Investigative Site
Shanghai, 200025
Novartis Investigative Site
Shanghai, 200032
Novartis Investigative Site
Shanghai, 200040
Novartis Investigative Site
Shanghai, 200080
Novartis Investigative Site
Shenyang, Liaoning, 110004
Novartis Investigative Site
Suzhou, Jiangsu, 215004
Novartis Investigative Site
Taiyuan, Shanxi, 030002
Novartis Investigative Site
Taizhou, Zhejiang, 318000
Novartis Investigative Site
Tianjin, Tianjin Municipality, 300121
Novartis Investigative Site
Tianjin, 300140
Novartis Investigative Site
Ürümqi, Xinjiang, 830001
Novartis Investigative Site
Ürümqi, Xinjiang, 830054
Novartis Investigative Site
Wuhan, Hubei, 430014
Novartis Investigative Site
Wuhan, Hubei, 430022
Novartis Investigative Site
Wuhan, Hubei, 430060
Novartis Investigative Site
Xiamen, 361004
Novartis Investigative Site
Xian, Shanxi, 710061
Novartis Investigative Site
Xuzhou, Jiangsu, 221003
Spain48 sites
Novartis Investigative Site
A Coruña, 15001
Novartis Investigative Site
A Coruña, 15006
Novartis Investigative Site
Alcorcón, Madrid, 28922
Novartis Investigative Site
Alicante, 03700
Novartis Investigative Site
Almería, 04009
Novartis Investigative Site
Barcelona, 08023
Novartis Investigative Site
Barcelona, 08025
Novartis Investigative Site
Barcelona, 08035
Novartis Investigative Site
Barcelona, 08036
Novartis Investigative Site
Barcelona, 08041
Novartis Investigative Site
Bilbao, Bizkaia, 48013
Novartis Investigative Site
Córdoba, 14004
Novartis Investigative Site
El Palmar, Murcia, 30120
Novartis Investigative Site
el Prat de Llobregat, Barcelona, 08820
Novartis Investigative Site
Ferrol, A Coruna, 15405
Novartis Investigative Site
Granada, 18016
Novartis Investigative Site
Huelva, 21080
Novartis Investigative Site
Jerez de la Frontera, Cadiz, 11407
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907
Novartis Investigative Site
Las Palmas GC, 35010
Novartis Investigative Site
Madrid, 28003
Novartis Investigative Site
Madrid, 28006
Novartis Investigative Site
Madrid, 28009
Novartis Investigative Site
Madrid, 28034
Novartis Investigative Site
Madrid, 28040
Novartis Investigative Site
Madrid, 28041
Novartis Investigative Site
Madrid, 28046
Novartis Investigative Site
Málaga, 29010
Novartis Investigative Site
Mallorca, Balearic Islands, 07198
Novartis Investigative Site
Palma, Balearic Islands, 07120
Novartis Investigative Site
Reus, Tarragona, 43204
Novartis Investigative Site
Sabadell, Barcelona, 08208
Novartis Investigative Site
Salamanca, 37005
Novartis Investigative Site
Salamanca, 37007
Novartis Investigative Site
San Sebastian Reyes, Madrid, 28702
Novartis Investigative Site
Sant Joan Despí, Barcelona, 08970
Novartis Investigative Site
Santander, Cantabria, 39008
Novartis Investigative Site
Santiago Compostela, A Coruna, 15706
Novartis Investigative Site
Seville, Andalusia, 41014
Novartis Investigative Site
Seville, 41009
Novartis Investigative Site
Seville, 41013
Novartis Investigative Site
Utrera, Sevilla, 41710
Novartis Investigative Site
Valencia, 46010
Novartis Investigative Site
Valencia, 46014
Novartis Investigative Site
Valladolid, 47011
Novartis Investigative Site
Vigo, Pontevedra, 36212
Novartis Investigative Site
Villamartín, Cadiz, 11650
Novartis Investigative Site
Zaragoza, 50009
India41 sites
Novartis Investigative Site
Ahmedabad, Gujarat, 380054
Novartis Investigative Site
Ahmedabad, Gujarat, 380060
Novartis Investigative Site
Ahmedabad, Gujarat, 382428
Novartis Investigative Site
Aligarh, Uttar Pradesh, 202002
Novartis Investigative Site
Belagavi, Karnataka, 590010
Novartis Investigative Site
Bikaner, Rajasthan, 334003
Novartis Investigative Site
Chennai, Tamil Nadu, 600006
Novartis Investigative Site
Coimbatore, Tamil Nadu, 641009
Novartis Investigative Site
Coimbatore, Tamil Nadu, 641037
Novartis Investigative Site
Dehradun, Uttarakhand, 248001
Novartis Investigative Site
Dehradun, Uttrakhand, 248104
Novartis Investigative Site
Ghaziabad, Uttar Pradesh, 201012
Novartis Investigative Site
Guntur, Andhra Pradesh, 522001
Novartis Investigative Site
Hyderabad, Andhra Pradesh, 500033
Novartis Investigative Site
Hyderabad, Telangana, 500034
Novartis Investigative Site
Indore, Madhyapradesh, 452003
Novartis Investigative Site
Kanpur, Uttar Pradesh, 208002
Novartis Investigative Site
Kochi, Kerala, 682018
Novartis Investigative Site
Kochi, Kerala, 682041
Novartis Investigative Site
Kolkata, West Bengal, 700054
Novartis Investigative Site
Kozhikode, Kerala, 673008
Novartis Investigative Site
Lucknow, Uttar Pradesh, 226003
Novartis Investigative Site
Madurai, Tamil Nadu, 625020
Novartis Investigative Site
Manipal, Karnataka, 576104
Novartis Investigative Site
Mumbai, Maharashtra, 400012
Novartis Investigative Site
Mysore, Karnataka, 570001
Novartis Investigative Site
Mysore, 570015
Novartis Investigative Site
Nagpur, Maharashtra, 440012
Novartis Investigative Site
Nagpur, Maharashtra, 440033
Novartis Investigative Site
Nashik, Maharashtra, 422005
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110060
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110075
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110076
Novartis Investigative Site
New Delhi, 110025
Novartis Investigative Site
Puducherry, 607402
Novartis Investigative Site
Pune, Maharashtra, 411004
Novartis Investigative Site
Pune, Maharashtra, 411045
Novartis Investigative Site
Secunderabad, Telangana, 500003
Novartis Investigative Site
Uttarakhand, 263153
Novartis Investigative Site
Vadodara, Gujarat, 390022
Novartis Investigative Site
Varanasi, Uttar Pradesh, 221010
Canada34 sites
Novartis Investigative Site
Calgary, Alberta, T2N 4N1
Novartis Investigative Site
Cambridge, Ontario, N1R 7R1
Novartis Investigative Site
Edmonton, Alberta, T5H 4B9
Novartis Investigative Site
Edmonton, Alberta, T6K 4C1
Novartis Investigative Site
Guelph, Ontario, N1H 1B1
Novartis Investigative Site
Halifax, Nova Scotia, B3H 2Y9
Novartis Investigative Site
Longueuil, British Columbia, J4H 4B9
Novartis Investigative Site
Moncton, New Brunswick, E1G 1A7
Novartis Investigative Site
Montreal, Quebec, H2X 1R9
Novartis Investigative Site
Montreal, Quebec, H3M 1L3
Novartis Investigative Site
Montreal, Quebec, H4N 2W2
Novartis Investigative Site
Newmarket, Ontario, L3Y 2P6
Novartis Investigative Site
North Vancouver, British Columbia, V7M 2H4
Novartis Investigative Site
Oakville, Ontario, L6K 3W7
Novartis Investigative Site
Peterborough, Ontario, K9J 0B2
Novartis Investigative Site
Québec, Quebec, G1V 4G5
Novartis Investigative Site
Québec, Quebec, G1W 4R4
Novartis Investigative Site
Québec, Quebec, G2J 0C4
Novartis Investigative Site
Saint-Jérôme, Quebec, J7Z 5T3
Novartis Investigative Site
Sainte-Foy, Quebec, G1V 4G2
Novartis Investigative Site
Sarnia, Ontario, N7T 4X3
Novartis Investigative Site
Scarborough Village, Ontario, M1B 4Z8
Novartis Investigative Site
Scarborough Village, Ontario, M1B 5N1
Novartis Investigative Site
Stoufville, Ontario, L4A 1H2
Novartis Investigative Site
Sydney, Nova Scotia, B1P 1P3
Novartis Investigative Site
Terrebonne, Quebec, J6V 2H2
Novartis Investigative Site
Trois-Rivières, Quebec, G8Z 3R9
Novartis Investigative Site
Vancouver, British Columbia, V5Z 1M9
Novartis Investigative Site
Vancouver, British Columbia, V6Z 1Y6
Novartis Investigative Site
Victoria, British Columbia, V8R4R2
Novartis Investigative Site
Victoria, British Columbia, V8T 5G4
Novartis Investigative Site
Victoria, British Columbia, V8V 4A1
Novartis Investigative Site
Winnipeg, Manitoba, R3C 0N2
Novartis Investigative Site
Winnipeg, Manitoba, R3L 1Z5
France32 sites
Novartis Investigative Site
Amiens, 80054
Novartis Investigative Site
Béziers, 34525
Novartis Investigative Site
Brest, 29200
Novartis Investigative Site
Chambray-lès-Tours, 37170
Novartis Investigative Site
Cholet, 49325
Novartis Investigative Site
Clermont-Ferrand, 63003
Novartis Investigative Site
Corbeil-Essonnes, 91100
Novartis Investigative Site
Grenoble, 38043
Novartis Investigative Site
Le Coudray, 28630
Novartis Investigative Site
Lille, 59000
Novartis Investigative Site
Limoges, Haute Vienne, 87000
Novartis Investigative Site
Lyon, 69007
Novartis Investigative Site
Marseille, 13885
Novartis Investigative Site
Metz, 57085
Novartis Investigative Site
Montauban, 82017
Novartis Investigative Site
Montpellier, 34295
Novartis Investigative Site
Nice, 06000
Novartis Investigative Site
Nîmes, 30029
Novartis Investigative Site
Orléans, 45100
Novartis Investigative Site
Paris, 75010
Novartis Investigative Site
Paris, 75013
Novartis Investigative Site
Paris, 75015
Novartis Investigative Site
Paris, 75018
Novartis Investigative Site
Pau, 64046
Novartis Investigative Site
Pessac, 33604
Novartis Investigative Site
Poitiers, 86021
Novartis Investigative Site
Reims, 51092
Novartis Investigative Site
Rennes, 35033
Novartis Investigative Site
Toulouse, 31054
Novartis Investigative Site
Tourcoing, 59208
Novartis Investigative Site
Valenciennes, 59300
Novartis Investigative Site
Villeneuve-d'Ascq, 59650
Brazil30 sites
Novartis Investigative Site
Aracaju, Sergipe, 49055-530
Novartis Investigative Site
Belo Horizonte, Minas Gerais, 30220-330
Novartis Investigative Site
Blumenau, Santa Catarina, 89020-430
Novartis Investigative Site
Brasília, Federal District, 70390-700
Novartis Investigative Site
Brasília, Federal District, 71625-009
Novartis Investigative Site
Campinas, São Paulo, 13060-080
Novartis Investigative Site
Campinas, 13092-133
Novartis Investigative Site
Canoas, Rio Grande do Sul, 92425-900
Novartis Investigative Site
Curitiba, Paraná, 80730-150
Novartis Investigative Site
Maceió, Alagoas, 57051-160
Novartis Investigative Site
Pelotas, Rio Grande do Sul, 96015-290
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90160-093
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90560-032
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, 90880-480
Novartis Investigative Site
Ribeirão Preto, São Paulo, 14048-900
Novartis Investigative Site
Rio de Janeiro, 20241-180
Novartis Investigative Site
Salvador, Estado de Bahia, 40170-130
Novartis Investigative Site
Santo André, São Paulo, 09030-010
Novartis Investigative Site
Santo André, São Paulo, 09060-870
Novartis Investigative Site
Santo André, São Paulo, 09090-790
Novartis Investigative Site
Sao Jose Rio Preto, São Paulo, 15015-750
Novartis Investigative Site
Sao Jose Rio Preto, São Paulo, 15090-000
Novartis Investigative Site
São Paulo, São Paulo, 01323-903
Novartis Investigative Site
São Paulo, São Paulo, 04005-003
Novartis Investigative Site
São Paulo, São Paulo, 04266-010
Novartis Investigative Site
São Paulo, São Paulo, 05403-000
Novartis Investigative Site
São Paulo, São Paulo, 09715-090
Novartis Investigative Site
São Paulo, 04026-090
Novartis Investigative Site
Uberlândia, Minas Gerais, 38400-500
Novartis Investigative Site
Vitória, Espírito Santo, 29055-450
Argentina29 sites
Novartis Investigative Site
Buenos Aires, C1012AAR
Novartis Investigative Site
Buenos Aires, C1425AGP
Novartis Investigative Site
Buenos Aires, C1428DCO
Novartis Investigative Site
Caba, Buenos Aires, C1119ACN
Novartis Investigative Site
Caba, C1427CCL
Novartis Investigative Site
CABA, Buenos Aires, C1056ABI
Novartis Investigative Site
CABA, Buenos Aires, C1187AAN
Novartis Investigative Site
CABA, Buenos Aires, C1221ADC
Novartis Investigative Site
CABA, Buenos Aires, C1280AEB
Novartis Investigative Site
CABA, Buenos Aires, C1405BCH
Novartis Investigative Site
CABA, Buenos Aires, C1426ABP
Novartis Investigative Site
Córdoba, X5002HWE
Novartis Investigative Site
Córdoba, X5016KET
Novartis Investigative Site
Corrientes, W3400CDS
Novartis Investigative Site
Formosa, P3600
Novartis Investigative Site
Mar del Plata, Buenos Aires, B7600ENA
Novartis Investigative Site
Mendoza, 5500
Novartis Investigative Site
Posadas, Misiones Province, N3300
Novartis Investigative Site
Quilmes, Buenos Aires, B1878GEG
Novartis Investigative Site
Ramos Mejía, Buenos Aires, B1704ETD
Novartis Investigative Site
Rosario, Santa Fe Province, S2000AII
Novartis Investigative Site
Rosario, Santa Fe Province, S2000CVD
Novartis Investigative Site
Rosario, Santa Fe Province, S2000DTB
Novartis Investigative Site
Salta, Salta Province, A4406BPF
Novartis Investigative Site
San Martín, Buenos Aires, B1650CSQ
Novartis Investigative Site
San Miguel de Tucumán, San Miguel de Tucuman, T4000ICL
Novartis Investigative Site
San Miguel Tucuman, Tucumán Province, T4000IFL
Novartis Investigative Site
Santa Fe, S3000EOZ
Novartis Investigative Site
Santa Fe, S3000FWO
Czechia26 sites
Novartis Investigative Site
Bedihošť, 798 21
Novartis Investigative Site
Brno, 602 00
Novartis Investigative Site
Brno, 625 00
Novartis Investigative Site
Brno, 638 00
Novartis Investigative Site
Český Krumlov, 381 01
Novartis Investigative Site
Hodonín, 695 01
Novartis Investigative Site
Hradec Králové, 500 05
Novartis Investigative Site
Jihlava, 586 01
Novartis Investigative Site
Louny, Czech Republic, 440 01
Novartis Investigative Site
Mariánské Lázně, 353 01
Novartis Investigative Site
Náchod, 547 01
Novartis Investigative Site
Ostrava, 700 30
Novartis Investigative Site
Ostrava, 710 00
Novartis Investigative Site
Ostrava, 738 01
Novartis Investigative Site
Pardubice, 532 03
Novartis Investigative Site
Polička, 57201
Novartis Investigative Site
Prague, 100 34
Novartis Investigative Site
Prague, 120 00
Novartis Investigative Site
Prague, 158 00
Novartis Investigative Site
Přerov, 751 52
Novartis Investigative Site
Příbram, 261 01
Novartis Investigative Site
Slaný, 274 01
Novartis Investigative Site
Svitavy, 568 25
Novartis Investigative Site
Třebíč, 674 01
Novartis Investigative Site
Uherské Hradiště, 686 01
Novartis Investigative Site
Zlín, 760 01
Poland25 sites
Novartis Investigative Site
Bialystok, 15-481
Novartis Investigative Site
Bialystok, 15-540
Novartis Investigative Site
Bydgoszcz, 85-065
Novartis Investigative Site
Gdansk, 80-952
Novartis Investigative Site
Gdynia, 81-423
Novartis Investigative Site
Kielce, 25-525
Novartis Investigative Site
Kłodzko, 57-300
Novartis Investigative Site
Krakow, 30-082
Novartis Investigative Site
Krakow, 30-363
Novartis Investigative Site
Krakow, 31-501
Novartis Investigative Site
Lodz, 93-513
Novartis Investigative Site
Lublin, 20-068
Novartis Investigative Site
Nowy Targ, Lesser Poland Voivodeship, 34-400
Novartis Investigative Site
Olsztyn, 10-165
Novartis Investigative Site
Ostrołęka, Masovian Voivodeship, 07-410
Novartis Investigative Site
Ostrowiec Swietok, 27-400
Novartis Investigative Site
Puławy, 24-100
Novartis Investigative Site
Ruda Śląska, 41-710
Novartis Investigative Site
Skierniewice, 96-100
Novartis Investigative Site
Sosnowiec, Silesian Voivodeship, 41-219
Novartis Investigative Site
Torun, 87-100
Novartis Investigative Site
Warsaw, 04-073
Novartis Investigative Site
Włocławek, 87-800
Novartis Investigative Site
Wroclaw, 53-673
Novartis Investigative Site
Zamość, 22-400
Bulgaria24 sites
Novartis Investigative Site
Burgas, 8000
Novartis Investigative Site
Haskovo, 6304
Novartis Investigative Site
Kyustendil, 2500
Novartis Investigative Site
Montana, 3400
Novartis Investigative Site
Pernik, 2300
Novartis Investigative Site
Pleven, 5800
Novartis Investigative Site
Plovdiv, 4000
Novartis Investigative Site
Rousse, 7000
Novartis Investigative Site
Rousse, 7012
Novartis Investigative Site
Sandanski, Blagoevgrad, 2850
Novartis Investigative Site
Sliven, 8800
Novartis Investigative Site
Sofia, Sofia-Grad, 1040
Novartis Investigative Site
Sofia, 1113
Novartis Investigative Site
Sofia, 1202
Novartis Investigative Site
Sofia, 1407
Novartis Investigative Site
Sofia, 1431
Novartis Investigative Site
Sofia, 1510
Novartis Investigative Site
Sofia, 1527
Novartis Investigative Site
Sofia, 1582
Novartis Investigative Site
Sofia, 1750
Novartis Investigative Site
Stamboliyski, 4210
Novartis Investigative Site
Stara Zagora, 6000
Novartis Investigative Site
Stara Zagora, 6003
Novartis Investigative Site
Veliko Tarnovo, 5000
Netherlands22 sites
Novartis Investigative Site
Alkmaar, North Holland, 1815 JD
Novartis Investigative Site
Amersfoort, 3813 TZ
Novartis Investigative Site
Amstelveen, North Holland, 1186 AM
Novartis Investigative Site
Amsterdam, North Holland, 1090 HM
Novartis Investigative Site
Amsterdam, North Holland, 1105 AZ
Novartis Investigative Site
Breda, North Brabant, 4818 CK
Novartis Investigative Site
Deventer, Overijssel, 7416 SE
Novartis Investigative Site
Doetinchem, Gelderland, 7009 BL
Novartis Investigative Site
Gouda, 2803 HH
Novartis Investigative Site
Groningen, 9713 GZ
Novartis Investigative Site
Groningen, 9728 NZ
Novartis Investigative Site
Heemstede, North Holland, 2035 RC
Novartis Investigative Site
Leeuwarden, Provincie Friesland, 8934 AD
Novartis Investigative Site
Leiden, South Holland, 2333 ZA
Novartis Investigative Site
Leiderdorp, South Holland, 2353 GA
Novartis Investigative Site
Meppel, Drenthe, 7943 KC
Novartis Investigative Site
Nijmegen, Gerlderland, 6532 SZ
Novartis Investigative Site
Nijmegen, 6525 GA
Novartis Investigative Site
Sneek, Provincie Friesland, 8601 ZK
Novartis Investigative Site
Tiel, Gelderland, 4002 WP
Novartis Investigative Site
Tilburg, North Brabant, 5042 AD
Novartis Investigative Site
Venlo, 5912 BL
Hungary20 sites
Novartis Investigative Site
Baja, 6500
Novartis Investigative Site
Balassagyarmat, 2660
Novartis Investigative Site
Balatonfüred, 8230
Novartis Investigative Site
Budapest, Pest County, 1134
Novartis Investigative Site
Budapest, 1083
Novartis Investigative Site
Budapest, 1145
Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, 4032
Novartis Investigative Site
Kalocsa, 6300
Novartis Investigative Site
Kecskemét, 6001
Novartis Investigative Site
Kistarcsa, 2143
Novartis Investigative Site
Komárom, 2921
Novartis Investigative Site
Nagykanizsa, 8800
Novartis Investigative Site
Oroshaza, Csongrád megye, 5900
Novartis Investigative Site
Orosháza, 5900
Novartis Investigative Site
Pécs, Baranya, 7623
Novartis Investigative Site
Pécs, 7623
Novartis Investigative Site
Szeged, 6725
Novartis Investigative Site
Szekszárd, 7100
Novartis Investigative Site
Szolnok, 5000
Novartis Investigative Site
Zalaegerszeg, 8900
Slovakia20 sites
Novartis Investigative Site
Banská Bystrica, 974 01
Novartis Investigative Site
Bardejov, 085 01
Novartis Investigative Site
Bratislava, 813 69
Novartis Investigative Site
Bratislava, 826 06
Novartis Investigative Site
Bratislava, 831 06
Novartis Investigative Site
Bratislava, 833 48
Novartis Investigative Site
Bratislava, 841 08
Novartis Investigative Site
Bratislava, 851 01
Novartis Investigative Site
Košice, 040 01
Novartis Investigative Site
Košice, 040 22
Novartis Investigative Site
Lučenec, 984 01
Novartis Investigative Site
Moldava nad Bodvou, 045 01
Novartis Investigative Site
Nitra, 949 01
Novartis Investigative Site
Nitra, 949 11
Novartis Investigative Site
Nové Zámky, 940 01
Novartis Investigative Site
Piešťany, 921 01
Novartis Investigative Site
Považská Bystrica, 017 01
Novartis Investigative Site
Prešov, 080 01
Novartis Investigative Site
Rožňava, 048 01
Novartis Investigative Site
Žilina, 010 01
Romania19 sites
Novartis Investigative Site
Baia Mare, Maramureş, 430123
Novartis Investigative Site
Brăila, ROM, 810249
Novartis Investigative Site
Brasov, 500283
Novartis Investigative Site
Bucharest, 011025
Novartis Investigative Site
Bucharest, 011461
Novartis Investigative Site
Bucharest, 021875
Novartis Investigative Site
Bucharest, 022328
Novartis Investigative Site
Bucharest, 050098
Novartis Investigative Site
Caracal, 235200
Novartis Investigative Site
Craiova, 200642
Novartis Investigative Site
Iași, 700503
Novartis Investigative Site
Oradea, 410169
Novartis Investigative Site
Piteşti, Argeş, 110424
Novartis Investigative Site
Târgu Mureş, Mureș County, 540124
Novartis Investigative Site
Târgu Mureş, 540143
Novartis Investigative Site
Timișoara, Timiș County, 300041
Novartis Investigative Site
Timișoara, Timiș County, 300480
Novartis Investigative Site
Timișoara, 300079
Novartis Investigative Site
Timișoara, 300359
South Africa18 sites
Novartis Investigative Site
Bloemfontein, Free State, 9301
Novartis Investigative Site
Bloemfontein, 9301
Novartis Investigative Site
Cape Town, Western Cape, 7130
Novartis Investigative Site
Cape Town, Western Cape, 7530
Novartis Investigative Site
Cape Town, ZAF, 7570
Novartis Investigative Site
Cape Town, 7500
Novartis Investigative Site
Centurion, 4001
Novartis Investigative Site
George, Western Cape, 6529
Novartis Investigative Site
Germiston, Gauteng, 1401
Novartis Investigative Site
Midrand, 1685
Novartis Investigative Site
Paarl, Western Cape, 7626
Novartis Investigative Site
Pretoria, Gauteng, 0002
Novartis Investigative Site
Pretoria, Gauteng, 0184
Novartis Investigative Site
Pretoria, 0181
Novartis Investigative Site
Somerset West, Western Cape, 7130
Novartis Investigative Site
Soweto, Gauteng, 2013
Novartis Investigative Site
Vereeniging, Gauteng, 1939
Novartis Investigative Site
Worcester, Western Cape, 6850
South Korea17 sites
Novartis Investigative Site
Bundang Gu, Gyeonggi-do, 13620
Novartis Investigative Site
Busan, 49201
Novartis Investigative Site
Cheongju-si, North Chungcheong, 28644
Novartis Investigative Site
Daegu, Dalseo Gu, 42602
Novartis Investigative Site
Daegu, 705703
Novartis Investigative Site
Daejeon, 302-241
Novartis Investigative Site
Gwangju, 61469
Novartis Investigative Site
Incheon, Korea, 405 760
Novartis Investigative Site
Jinju, Gyeongsangnam-do, 52727
Novartis Investigative Site
Seoul, Korea, 02447
Novartis Investigative Site
Seoul, Korea, 08308
Novartis Investigative Site
Seoul, 03080
Novartis Investigative Site
Seoul, 03722
Novartis Investigative Site
Seoul, 06351
Novartis Investigative Site
Seoul, 06591
Novartis Investigative Site
Wŏnju, Gangwon-do, 26426
Novartis Investigative Site
Yangsan, Gyeongsangnam-do, 50612
Australia16 sites
Novartis Investigative Site
Adelaide, South Australia, 5000
Novartis Investigative Site
Auchenflower, Queensland, 4066
Novartis Investigative Site
Bedford Park, South Australia, 5041
Novartis Investigative Site
Botany, New South Wales, 2019
Novartis Investigative Site
Clayton, Victoria, 3168
Novartis Investigative Site
Geelong, Victoria, 3220
Novartis Investigative Site
Joondalup, Western Australia, 6027
Novartis Investigative Site
Leabrook, South Australia, 5068
Novartis Investigative Site
Liverpool, 2170
Novartis Investigative Site
Malvern East, Victoria, 3145
Novartis Investigative Site
Milton, Queensland, 4064
Novartis Investigative Site
Nedlands, Western Australia, 6009
Novartis Investigative Site
New Lambton Heights, New South Wales, 2305
Novartis Investigative Site
Richmond, Victoria, 3121
Novartis Investigative Site
Woodville South, South Australia, 5011
Novartis Investigative Site
Woolloongabba, Queensland, 4102
Italy16 sites
Novartis Investigative Site
Bologna, BO, 40133
Novartis Investigative Site
Bologna, BO, 40138
Novartis Investigative Site
Brescia, BS, 25123
Novartis Investigative Site
Cona, FE, 44124
Novartis Investigative Site
Florence, FI, 50134
Novartis Investigative Site
Grosseto, GR, 58100
Novartis Investigative Site
Milan, MI, 20132
Novartis Investigative Site
Milan, MI, 20138
Novartis Investigative Site
Milan, MI, 20162
Novartis Investigative Site
Modena, MO, 41126
Novartis Investigative Site
Pordenone, PN, 33170
Novartis Investigative Site
Pozzilli, IS, 86077
Novartis Investigative Site
Rozzano, MI, 20089
Novartis Investigative Site
Sassari, SS, 07100
Novartis Investigative Site
Siena, SI, 53100
Novartis Investigative Site
Torino, TO, 10126
Mexico14 sites
Novartis Investigative Site
Acapulco, 39570
Novartis Investigative Site
Aguascalientes, 20230
Novartis Investigative Site
Chihuahua City, 31203
Novartis Investigative Site
Durango, 34000
Novartis Investigative Site
Guadalajara, Jalisco, 44210
Novartis Investigative Site
Guadalajara, Jalisco, 44600
Novartis Investigative Site
Guadalajara, Jalisco, 44670
Novartis Investigative Site
Guadalajara, 44360
Novartis Investigative Site
Mérida, Yucatán, 97070
Novartis Investigative Site
Mexico City, Mexico City, 06700
Novartis Investigative Site
Monterrey, Nuevo León, 64710
Novartis Investigative Site
Tlalnepantla, State of Mexico, 54055
Novartis Investigative Site
Xalapa, 91020
Novartis Investigative Site
Xalapa, 91193
Belgium13 sites
Novartis Investigative Site
Antwerp, 2020
Novartis Investigative Site
Brasschaat, 2930
Novartis Investigative Site
Bruges, 8000
Novartis Investigative Site
Brussels, 1020
Novartis Investigative Site
Charleroi, 6000
Novartis Investigative Site
Edegem, 2650
Novartis Investigative Site
Genk, Limburg, 3600
Novartis Investigative Site
Ghent, 9000
Novartis Investigative Site
Kortrijk, West-Vlaanderen, 8500
Novartis Investigative Site
La Louvière, 7100
Novartis Investigative Site
Roeselare, West-Vlaanderen, 8800
Novartis Investigative Site
Ronse, 9600
Novartis Investigative Site
Yvoir, Namur, 5530
Colombia13 sites
Novartis Investigative Site
Barranquilla, Atlántico, 080002
Novartis Investigative Site
Barranquilla, Atlántico, 080020
Novartis Investigative Site
Barranquilla, 080020
Novartis Investigative Site
Bogotá, 110221
Novartis Investigative Site
Cali, Valle del Cauca Department, 760001
Novartis Investigative Site
Cali, Valle del Cauca Department, 760032
Novartis Investigative Site
Cali, 760024
Novartis Investigative Site
Cartagena, Departamento de Bolívar, 130001
Novartis Investigative Site
Floridablanca, 681017
Novartis Investigative Site
Manizales, Caldas Department, 170001
Novartis Investigative Site
Medellín, Antioquia, 050021
Novartis Investigative Site
Medellín, Antioquia, 050036
Novartis Investigative Site
Pereira, Risaralda Department, 660003
Japan12 sites
Novartis Investigative Site
Chikushino-shi, Fukuka, 8188516
Novartis Investigative Site
Fujisawa, Kanagawa, 2518550
Novartis Investigative Site
Izumisano, Osaka, 5988577
Novartis Investigative Site
Kanazawa, Ishikawa-ken, 9208650
Novartis Investigative Site
Kawaguchi, Saitama, 3328558
Novartis Investigative Site
Komatsu, Ishikawa-ken, 9230961
Novartis Investigative Site
Nagaoka, Niigata, 9408621
Novartis Investigative Site
Nagasaki, 8508555
Novartis Investigative Site
Odawara, Kanagawa, 2508558
Novartis Investigative Site
Osaka, Osaka, 5400006
Novartis Investigative Site
Toyota, Aichi-ken, 4718513
Novartis Investigative Site
Yokohama, Kanagawa, 2478581
Portugal12 sites
Novartis Investigative Site
Alcabideche, 2755-009
Novartis Investigative Site
Almada, 2805-267
Novartis Investigative Site
Carnaxide, 2799-523
Novartis Investigative Site
Coimbra, 3004-561
Novartis Investigative Site
Guimarães, 4835-044
Novartis Investigative Site
Leiria, 2410-197
Novartis Investigative Site
Lisbon, 1500-650
Novartis Investigative Site
Lisbon, 1649-035
Novartis Investigative Site
Matosinhos Municipality, 4454-513
Novartis Investigative Site
Santa Maria da Feira, 4520-211
Novartis Investigative Site
Vila Nova de Gaia, 4434-502
Novartis Investigative Site
Vila Real, 5000-508
Serbia12 sites
Novartis Investigative Site
Belgrade, 11000
Novartis Investigative Site
Belgrade, 11070
Novartis Investigative Site
Belgrade, 11080
Novartis Investigative Site
Ćuprija, 35230
Novartis Investigative Site
Kamenitz, 21204
Novartis Investigative Site
Kragujevac, 34000
Novartis Investigative Site
Leskovac, 16000
Novartis Investigative Site
Niš, 18000
Novartis Investigative Site
Smederevo, 26000
Novartis Investigative Site
Subotica, 24000
Novartis Investigative Site
Vranje, 17500
Novartis Investigative Site
Zaječar, 19000
Chile9 sites
Novartis Investigative Site
La Serena, Coquimbo Region, 1720430
Novartis Investigative Site
Osorno, Los Lagos Region, 5290000
Novartis Investigative Site
Santiago, Santiago Metropolitan, 7500710
Novartis Investigative Site
Santiago, Santiago Metropolitan, 8331143
Novartis Investigative Site
Santiago, Santiago Metropolitan, 8380465
Novartis Investigative Site
Santiago, 8380456
Novartis Investigative Site
Temuco, Araucania, 4781156
Novartis Investigative Site
Victoria, Araucania, 4720097
Novartis Investigative Site
Viña del Mar, Valparaiso, 2520997
Denmark9 sites
Novartis Investigative Site
Aarhus N, 8200
Novartis Investigative Site
Esbjerg, 6700
Novartis Investigative Site
Glostrup Municipality, 2600
Novartis Investigative Site
Herlev, 2730
Novartis Investigative Site
Herning, Central Jutland, 7400
Novartis Investigative Site
Hjørring, 9800
Novartis Investigative Site
Roskilde, 4000
Novartis Investigative Site
Svendborg, 5700
Novartis Investigative Site
Viborg, 8800
Lithuania9 sites
Novartis Investigative Site
Kaunas, Kaunas County, LT-50177
Novartis Investigative Site
Kaunas, LTU, LT 50161
Novartis Investigative Site
Kaunas, 49449
Novartis Investigative Site
Kaunas, LT-50009
Novartis Investigative Site
Klaipėda, Klaipėda County, 92288
Novartis Investigative Site
Panevezys, 35144
Novartis Investigative Site
Šiauliai, LTU, LT-77156
Novartis Investigative Site
Šiauliai, 76206
Novartis Investigative Site
Vilnius, LT-08406
Sweden9 sites
Novartis Investigative Site
Falun, 791 82
Novartis Investigative Site
Gothenburg, Västra Götaland County, 416 85
Novartis Investigative Site
Gothenburg, 412 55
Novartis Investigative Site
Lund, 221 85
Novartis Investigative Site
Malmö, 214 28
Novartis Investigative Site
Stockholm, SE, 141 86
Novartis Investigative Site
Stockholm, 111 57
Novartis Investigative Site
Stockholm, 17176
Novartis Investigative Site
Västerås, 721 89
Turkey (Türkiye)9 sites
Novartis Investigative Site
Adana, Yuregir, 01230
Novartis Investigative Site
Ankara, Sihhiye-Altindag, 06230
Novartis Investigative Site
Ankara, Yenimahalle, 06170
Novartis Investigative Site
Bursa, Nilufer, 16140
Novartis Investigative Site
Istanbul, Fatih, 34098
Novartis Investigative Site
Istanbul, Kartal, 34865
Novartis Investigative Site
Istanbul, 34147
Novartis Investigative Site
Izmir, Balcova, 35340
Novartis Investigative Site
Konya, Selcuklu, 42130
Croatia8 sites
Novartis Investigative Site
Čakovec, 40000
Novartis Investigative Site
Krapinske Toplice, 49217
Novartis Investigative Site
Opatija, 51410
Novartis Investigative Site
Osijek, 31000
Novartis Investigative Site
Rijeka, 51000
Novartis Investigative Site
Slavonski Brod, 35000
Novartis Investigative Site
Split, 21000
Novartis Investigative Site
Zagreb, 10000
Israel8 sites
Novartis Investigative Site
Ashdod, 7747629
Novartis Investigative Site
Holon, 5822012
Novartis Investigative Site
Jerusalem, 9112001
Novartis Investigative Site
Nahariya, 2210001
Novartis Investigative Site
Petah Tikva, 4941492
Novartis Investigative Site
Ramat Gan, 5265601
Novartis Investigative Site
Sefad, 1311300
Novartis Investigative Site
Tsrifin, 7030000
Latvia8 sites
Novartis Investigative Site
Daugavpils, LV-5417
Novartis Investigative Site
Kuldīga, LV-3300
Novartis Investigative Site
Liepāja, LV, LV-3414
Novartis Investigative Site
Riga, LV, 1038
Novartis Investigative Site
Riga, 1012
Novartis Investigative Site
Riga, LV 1002
Novartis Investigative Site
Riga, LV-1001
Novartis Investigative Site
Valmiera, 4201
Norway8 sites
Novartis Investigative Site
Arendal, 4838
Novartis Investigative Site
Drammen, 3004
Novartis Investigative Site
Nordbyhagen, Oslo, 1478
Novartis Investigative Site
Oslo, 0407
Novartis Investigative Site
Oslo, 0514
Novartis Investigative Site
Skedsmokorset, 2020
Novartis Investigative Site
Stavanger, 4019
Novartis Investigative Site
Tromsø, 9038
Estonia7 sites
Novartis Investigative Site
Pärnu, 80018
Novartis Investigative Site
Tallinn, 10117
Novartis Investigative Site
Tallinn, 10138
Novartis Investigative Site
Tallinn, 13419
Novartis Investigative Site
Tallinn, 13619
Novartis Investigative Site
Tartu, 50406
Novartis Investigative Site
Tartu, 50708
New Zealand7 sites
Novartis Investigative Site
Auckland, 0740
Novartis Investigative Site
Christchurch, 8001
Novartis Investigative Site
Christchurch, 8140
Novartis Investigative Site
Dunedin, NZW, 9016
Novartis Investigative Site
Grafton, Auckland, 1023
Novartis Investigative Site
Hamilton, 3204
Novartis Investigative Site
Lower Hutt, 5040
Taiwan7 sites
Novartis Investigative Site
Kaohsiung City, 80756
Novartis Investigative Site
Tainan, 704302
Novartis Investigative Site
Tainan, 71004
Novartis Investigative Site
Taipei, 10002
Novartis Investigative Site
Taipei, 10449
Novartis Investigative Site
Taipei, 110
Novartis Investigative Site
Taipei, 11217
Greece6 sites
Novartis Investigative Site
Athens, 115 21
Novartis Investigative Site
Athens, 115 27
Novartis Investigative Site
Athens, 11528
Novartis Investigative Site
Ioannina, 455 00
Novartis Investigative Site
Larissa, 411 10
Novartis Investigative Site
Thessaloniki, 570 01
Malaysia6 sites
Novartis Investigative Site
Alor Star, Kedah, 05460
Novartis Investigative Site
Ipoh, Perak, 30450
Novartis Investigative Site
Kuala Lumpur, Selangor, 43000
Novartis Investigative Site
Kuala Lumpur, 56000
Novartis Investigative Site
Kuala Lumpur, 59100
Novartis Investigative Site
Kuantan, Pahang, 25100
Thailand6 sites
Novartis Investigative Site
Bangkok, 10400
Novartis Investigative Site
Bangkok, 10700
Novartis Investigative Site
Chiang Mai, 50200
Novartis Investigative Site
Muang, Thailand, 12120
Novartis Investigative Site
Muang, 40002
Novartis Investigative Site
Songkhla, Hat Yai, 90110
Finland5 sites
Novartis Investigative Site
Helsinki, 00370
Novartis Investigative Site
Jyväskylä, 40620
Novartis Investigative Site
Kuopio, Northern Savonia, 70600
Novartis Investigative Site
Turku, 20100
Novartis Investigative Site
Turku, 20520
Puerto Rico5 sites
Advanced Clinical Research LLC
Bayamón, 00959
Research and Cardiovascular Corp
Ponce, 00717-1322
Latin Clinical Trial Center Inc
San Juan, 00909
Advance Medical Research Center
San Juan, 00926
Barbara Diaz Hernandez Research Inc
San Juan, 00926
Philippines4 sites
Novartis Investigative Site
Iloilo City, 5000
Novartis Investigative Site
Quezon, 1102
Novartis Investigative Site
San Fernando City, Pampanga, 2000
Novartis Investigative Site
San Juan City, 1502
Russia4 sites
Novartis Investigative Site
Moscow, 127473
Novartis Investigative Site
Ryazan, 390039
Novartis Investigative Site
Saint Petersburg, 195197
Novartis Investigative Site
Yaroslavl, 150062
Singapore4 sites
Novartis Investigative Site
Singapore, 119074
Novartis Investigative Site
Singapore, 169609
Novartis Investigative Site
Singapore, 529889
Novartis Investigative Site
Singapore, 768828
Slovenia4 sites
Novartis Investigative Site
Celje, 3000
Novartis Investigative Site
Ljubljana, 1000
Novartis Investigative Site
Ptuj, 2250
Novartis Investigative Site
Slovenj Gradec, 2380
Austria2 sites
Novartis Investigative Site
Braunau am Inn, 5280
Novartis Investigative Site
Graz, 8036
Iceland2 sites
Novartis Investigative Site
Kopavogur, 201
Novartis Investigative Site
Reykjavik, 101
Mauritius2 sites
Novartis Investigative Site
Phoenix, 73408
Novartis Investigative Site
Solferino Phoenix, Mauritius, 1772
About this study
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Read the detailed description
Purpose of this study is to test the hypothesis that treatment with inclisiran sodium 300 mg s.c. administered on Day 1, Month 3 (Day 90), and every 6 months thereafter taken in addition to well-tolerated high-intensity statin therapy in participants with established ASCVD will significantly reduce the risk of 3-Point-Major Adverse Cardiovascular Events (3P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI) and non-fatal ischemic stroke. This will be compared to placebo in adjunct to well-tolerated high-intensity statin therapy.
- Conditions
- Atherosclerotic Cardiovascular Disease
- Being tested
- Inclisiran sodium 300 mg, Placebo
- Keywords
- Atherosclerotic cardiovascular disease, Hypercholesterolemia, Dyslipidemia, high cholesterol, Hyperlipidemia, Inclisiran, siRNA, KJX839
- Medical subject headings
- Atherosclerosis, Hypercholesterolemia, Dyslipidemias, Hyperlipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inclisiran sodium 300 mgDrug
Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
PlaceboDrug
Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
| Study group | Role | What they receive |
|---|---|---|
| Inclisiran sodium | Experimental | Subcutaneous injection Receives: Drug: Inclisiran sodium 300 mg |
| Placebo | Placebo comparator | Subcutaneous injection Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events)
3P-MACE is a confirmed composite endpoint which includes cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke.
Measured: From randomization to total follow-up time (up to 72 months)
Secondary outcomes (4)
Time to Occurrence of Cardiovascular (CV) Death
CV death is defined as death due to cardiovascular events
Measured: From randomization to total follow-up time (up to 72 months)
Time to First Occurrence of 4P-MACE (4-Point Major Adverse Cardiovascular Events)
A composite 4P- MACE is defined as CV death, non-fatal MI, non-fatal ischemic stroke and urgent coronary revascularization.
Measured: From randomization to total follow-up time (up to 72 months)
Time to first occurrence of Major Limb Adverse Events (MALE)
Major Limb Adverse Events including acute lower limb ischemia, lower limb amputation due to ischemia, or urgent lower limb revascularization for ischemia
Measured: From randomization to total follow-up time (up to 72 months)
Time to occurrence of all-cause death
All-Cause death is defined as: all deaths from randomization until up to 72 months
Measured: From randomization to total follow-up time (up to 72 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2021
- Study start23 Nov 2021
- Primary completion10 May 2027 (estimated)
- Study completion10 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Atherosclerotic Cardiovascular DiseaseStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized, double-blind, parallel group, placebo-controlled, multi-center, event-driven study
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 17,004 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05030428
- Sponsor's protocol ID
- CKJX839B12302
- Acronym
- VICTORION-2P
- Status last verified
- Aug 2026
- First submitted
- 17 Aug 2021
- Last updated
- 25 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Publications
Steg PG, Goodman SG, Jukema JW, Martens P, Zirlik A, Bhatt DL, Menon V, Szarek M, Lesogor A, Stratz C, O'Donoghue F, Mena-Madrazo J, Shao Q, Liu K, Mehran R; VICTORION-2 Prevent Investigators. Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. Am Heart J. 2026 Oct;300:107493. doi: 10.1016/j.ahj.2026.107493. Epub 2026 May 26.
PubMed 42203164
Study at a glance
From the registry record, last updated by the sponsor on 25 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
- ClinicalTrials.gov ID
- NCT05030428
- Acronym / sponsor ID
- VICTORION-2P / CKJX839B12302
- Conditions
- Atherosclerotic Cardiovascular Disease
- Keywords
- Atherosclerotic cardiovascular disease, Hypercholesterolemia, Dyslipidemia, high cholesterol, Hyperlipidemia, Inclisiran, siRNA, KJX839
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 17,004 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 23 Nov 2021 (actual)
- Primary completion
- 10 May 2027 (estimated)
- Study completion
- 10 May 2027 (estimated)
- First posted
- 1 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants with established cardiovascular disease (CVD).
Detailed description
Purpose of this study is to test the hypothesis that treatment with inclisiran sodium 300 mg s.c. administered on Day 1, Month 3 (Day 90), and every 6 months thereafter taken in addition to well-tolerated high-intensity statin therapy in participants with established ASCVD will significantly reduce the risk of 3-Point-Major Adverse Cardiovascular Events (3P-MACE) defined as a composite of CV death, non-fatal myocardial infarction (MI) and non-fatal ischemic stroke. This will be compared to placebo in adjunct to well-tolerated high-intensity statin therapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- randomized, double-blind, parallel group, placebo-controlled, multi-center, event-driven study
| Arm | Type | Receives |
|---|---|---|
| Inclisiran sodium | Experimental | Drug: Inclisiran sodium 300 mgSubcutaneous injection |
| Placebo | Placebo comparator | Drug: PlaceboSubcutaneous injection |
Who may qualify
- Ages
- 40 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Fasting LDL-C ≥ 70 mg/dL at randomization visit
- Stable (greater than or equal to 4 weeks) and well-tolerated lipid-lowering regimen (including e.g. with or without Ezetimibe) that must include a high-intensity statin therapy with either atorvastatin greater than or equal to 40 mg QD or rosuvastatin greater than or equal to 20 mg QD
- Established CV disease defined as ANY of the following three conditions
Key exclusion criteria (10 listed)
- Acute coronary syndrome, stroke, peripheral arterial revascularization procedure or amputation due to atherosclerotic disease < 4 weeks before screening visit
- Treatment with PCSK9 inhibitors (e.g. evolocumab, alirocumab) within 90 days or planned use post first study visit
- Planned or expected cardiac, cerebrovascular or peripheral artery surgery or re-vascularization within the 6 months after the first study visit
- Heart failure NYHA class III or IV
- Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inclisiran sodium 300 mgSubcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit | Drug | Inclisiran sodium |
| PlaceboSubcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit | Drug | Placebo |
Primary outcome
Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events)
Time frame: From randomization to total follow-up time (up to 72 months)
3P-MACE is a confirmed composite endpoint which includes cardiovascular death, non-fatal myocardial infarction and non-fatal ischemic stroke.
4 secondary outcomes
Time to Occurrence of Cardiovascular (CV) Death
Time frame: From randomization to total follow-up time (up to 72 months)
Time to First Occurrence of 4P-MACE (4-Point Major Adverse Cardiovascular Events)
Time frame: From randomization to total follow-up time (up to 72 months)
Time to first occurrence of Major Limb Adverse Events (MALE)
Time frame: From randomization to total follow-up time (up to 72 months)
Time to occurrence of all-cause death
Time frame: From randomization to total follow-up time (up to 72 months)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Aug 2026.
- Derived from this study: PubMed 42203164Steg PG, Goodman SG, Jukema JW, Martens P, Zirlik A, Bhatt DL, Menon V, Szarek M, Lesogor A, Stratz C, O'Donoghue F, Mena-Madrazo J, Shao Q, Liu K, Mehran R; VICTORION-2 Prevent Investigators. Design of VICTORION-2 Prevent: A randomized double-blind, placebo-controlled trial, assessing the impact of inclisiran on major adverse cardiovascular events in patients with established cardiovascular disease. Am Heart J. 2026 Oct;300:107493. doi: 10.1016/j.ahj.2026.107493. Epub 2026 May 26.
- Individual participant dataSharing planned: Yes. Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Related trials for Atherosclerotic Cardiovascular Disease
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
983 sites in 50 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Inclisiran sodium 300 mg in people with Atherosclerotic Cardiovascular Disease, run by Novartis Pharmaceuticals at 983 sites in 50 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 25 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 983 sites in United States, China, Spain, India, Canada and 45 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Time to First Occurrence of 3P-MACE (3-Point Major Adverse Cardiovascular Events) (time frame: From randomization to total follow-up time (up to 72 months)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05030428, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Aug 2026.